May 13, 2020 / 10:27 PM / 19 days ago

BRIEF-Galera Therapeutics Says New Data From A Phase 2B Trial On Chronic Kidney Disease To Be Presented At ASCO 2020

May 13 (Reuters) - Galera Therapeutics Inc:

* GALERA THERAPEUTICS ANNOUNCES NEW DATA FROM THE PHASE 2B TRIAL ON THE EFFECT OF AVASOPASEM MANGANESE ON CISPLATIN-INDUCED CHRONIC KIDNEY DISEASE TO BE PRESENTED AT ASCO 2020 VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below